Squalamine lactate preserves vision in phase II trial
June 1st 2005Key Biscayne, FL—In a small, phase II clinical trial of squalamine lactate (Evizon, Genaera Corp.), a systemically delivered drug for the treatment of choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD), all patients who received a 40-mg dose had preserved or improved vision through a 4-month study period, reported Carl Regillo, MD, FACS.
Clinical landscape of neovascular AMD is changing
June 1st 2005In the world of eye care, therapy for age-related macular degeneration (AMD) presents as an urgent medical need both now and for future generations. Neovascular AMD accounts for 20% of total AMD cases, but 90% of the severe loss of vision that is associated with the disease, and there are more than 200,000 new cases of neovascular AMD each year.
Transient monocular visual loss exam must be thorough
June 1st 2005Salt Lake City—Transient monocular visual loss, amaurosis fugax, is a common complaint that ophthalmologists encounter. The challenge for the ophthalmologist is to determine if the cause is benign or of a more serious vascular origin. Kathleen Digre, MD, described the step-by-step approach to discovering the answer.
Know what to look for in the case of AVMs
June 1st 2005New York—Some cerebrovascular events, such as arteriovenous malformations (AVMs) and aneurysms of the brain, occur far less often than migraines and strokes but nevertheless may present in the ophthalmologist's office. With this type of pathology that has ocular manifestations, the ophthalmologist may be one of the first specialists to examine the patient, and knowing what to look for is of paramount importance.
Ophthalmologist travels to Zambia to help those in need
June 1st 2005As physicians, my wife and I spent 2 weeks in Zambia with a group of 20 other professionals from the United States and United Kingdom. The expertise included banking, foundation management, real estate development, teaching, communications, and medicine.
TASS may be effect of cataract/anterior segment surgery
June 1st 2005Salt Lake City—Toxic anterior segment syndrome (TASS) is an acute noninfectious inflammatory event that usually occurs within 12 to 24 hours following cataract/ anterior segment surgery. Surgeons need to differentiate between TASS and endophthalmitis and carefully determine the cause of the syndrome, according to Nick Mamalis, MD.
More surgeons adopting 25-gauge vitrectomy technique
June 1st 2005Minimally invasive, sutureless, 25-gauge vitrectomy has been an option for only a few years but appears to be gaining converts, although with widespread acknowledgment that the system has limitations when compared with the well-established 20-gauge technology.
Interim results favorable for dye-enhanced feeder vessel treatment
June 1st 2005Key Biscayne, FL—Preliminary analyses from a phase II study demonstrate the feasibility of dye-enhanced photocoagulation (DEP) feeder vessel treatment (FVT) in eyes with minimally classic choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD). This new technique may have benefits compared with laser photocoagulation FVT alone for both increasing the efficiency of the procedure and allowing for treatment of larger diameter vessels, said Giovanni Staurenghi, MD, at the annual meeting of the Macula Society.
Baseline vision influences role of submacular surgery in NIH-sponsored trial
June 1st 2005Baltimore—Results from the Group H Submacular Surgery Trial (SST), sponsored by the National Eye Institute of the National Institutes of Health (NIH), support consideration of surgical removal of subfoveal choroidal neovascularization (CNV) in eyes with poorer vision as measured in the SST and vessel growth that is idiopathic or associated with the ocular histoplasmosis syndrome, said Neil M. Bressler, MD, at the Current Concepts in Ophthalmology meeting.
Counter pressure device 100% effective in controlling drug reflux
June 1st 2005Tucson, AZ—Use of a counter-pressure device (CPD) during the posterior juxtascleral administration of anecortave acetate for depot suspension (Retaane, Alcon Laboratories) effectively eliminates reflux to ensure consistent drug delivery, according to the results of a clinical pharmacokinetics study.
Squalamine lactate preserves vision in phase II trial
June 1st 2005Key Biscayne, FL—In a small, phase II clinical trial of squalamine lactate (Evizon, Genaera Corp.), a systemically delivered drug for the treatment of choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD), all patients who received a 40-mg dose had preserved or improved vision through a 4-month study period, reported Carl Regillo, MD, FACS.
Anti-VEGF drug helps improve vision in wet AMD
June 1st 2005Key Biscayne, FL—Early results from the Systemic Avastin for Neovascular Age-Related Macular Degeneration (SANA) Study showed that bevacizumab (Avastin, Genentech) improved vision and substantially reduced leakage from abnormal blood vessels in eyes of patients with neovascular (wet) age-related macular degeneration (AMD), said Philip Rosenfeld, MD, PhD.
Intravitreal steroid injections suggested for treatment of various retinal diseases
June 1st 2005New York—Intravitreal steroid injections are gaining credence for their utility in a variety of eye diseases, but they also carry risks that have not yet been fully investigated, said Richard F. Spaide, MD.
Eyetech aims to be retina specialists' biotech resource
June 1st 2005For senior executives at Eyetech Pharmaceuticals, New York, the 24 mm that encompass the eye—and in particular the back of the eye—is a vast frontier waiting to be explored. The small biotech company sees it as an opportunity to deliver medical solutions for the betterment of patients who suffer from blinding eye diseases. This is the direction that Eyetech is taking its future.
Fluocinolone acetonide implant heralds advances in posterior uveitis
June 1st 2005On April 11, Bausch & Lomb announced that it had received FDA approval to market its intravitreal fluocinolone acetonide implant 0.59 mg (Retisert) for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye.
Fluidics play role in improving safety, efficacy of phacoemulsification
June 1st 2005Washington, DC—Cataract surgery has improved in terms of safety and efficacy with the introduction of phaco, foldable IOLs, and the use of smaller incisions. With a better understanding of fluidics —infusion and aspiration—surgeons will continue to improve the safety and efficacy of phaco.
Site-active steroid provides symptomatic relief for patients with dry eye disease
May 15th 2005Miami—Anti-inflammatory treatment using loteprednol etabonate suspension 0.2% (Alrex, Bausch & Lomb) appears to offer a safe and useful option for symptomatic relief in patients with dry eye, according to Roberto Beraja, MD.
Give your staff tools they need for contact lens dispensing
May 15th 2005Contact lens dispensing is an important addition to any dispensary. In fact, in today's general ophthalmology practice, dispensing all eyewear, including contact lenses, is practically a necessity. With excellent planning and efficient office procedures, the contact lens dispensing can be a profitable venture that enhances patient experiences, reminding them of the excellent medical care they are given at the office.